临床上已证实干扰素(IFN)治疗慢性丙型肝炎有效,但普遍认为对进展至肝硬化者无效。为评价IFN治疗肝硬化患者的疗效和安全性,作者以人类淋巴细胞IFN(L-IFN)随机对照治疗代偿期丙型肝炎肝硬化患者。 30例慢性丙型肝炎患者中,男14例,女16例,年龄52～74岁,平均60.1岁。患者仅有轻度乏力及低热,组织学证实为肝硬化并有门静脉高压症状和脾脏肿大,按Child分级属于A Interferon (IFN) has been clinically proven to be effective in the treatment of chronic hepatitis C, but is generally considered to be ineffective in progression to cirrhosis. To evaluate the efficacy and safety of IFN in patients with cirrhosis, the authors randomized patients with hepatitis C cirrhosis to treatment with human lymphocyte IFN (L-IFN). Thirty patients with chronic hepatitis C, 14 males and 16 females, aged 52 to 74 years, mean 60.1 years. Patients with mild fatigue and fever only, histologically confirmed cirrhosis and portal hypertension and splenomegaly, according to Child classification is A